Forlong Biotechnology doses first patient in Australian Phase 1 trial of subcutaneous FL115
Forlong Biotechnology begins Australian Phase 1 testing of subcutaneous FL115, targeting lower peak exposure and improved immune activation.
Pharma & Biotech
Medical Devices & Diagnostics
Everlab’s AU$65m Series A raises the stakes for preventive health platforms
Find out how Everlab’s AU$65m Series A could reshape AI preventive healthcare, diagnostics, patient data and scalable care access.